Wedbush Cuts Aprea Therapeutics (NASDAQ:APRE) Price Target to $3.00

Aprea Therapeutics (NASDAQ:APRE) had its price target decreased by Wedbush to $3.00 in a research note issued to investors on Thursday,Benzinga reports. Wedbush currently has an outperform rating on the stock.

Other analysts also recently issued reports about the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aprea Therapeutics in a research report on Friday, July 17th. Oppenheimer began coverage on shares of Aprea Therapeutics in a research report on Thursday, May 7th. They set an “outperform” rating and a $5.00 price target for the company. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Aprea Therapeutics currently has an average rating of “Hold” and an average target price of $3.07.

Aprea Therapeutics Stock Up 1.3%

NASDAQ APRE opened at $0.68 on Thursday. The firm has a market capitalization of $8.56 million, a PE ratio of -0.63 and a beta of 1.52. The stock’s 50 day moving average is $0.70 and its 200 day moving average is $0.77. Aprea Therapeutics has a twelve month low of $0.55 and a twelve month high of $1.75.

Aprea Therapeutics (NASDAQ:APRE) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.11. Aprea Therapeutics had a negative return on equity of 47.60% and a negative net margin of 4,405.59%. On average, research analysts anticipate that Aprea Therapeutics will post -0.32 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Jane Street Group LLC purchased a new position in Aprea Therapeutics during the fourth quarter valued at $40,000. DRW Securities LLC purchased a new stake in shares of Aprea Therapeutics in the fourth quarter worth $103,000. Finally, AIGH Capital Management LLC increased its holdings in shares of Aprea Therapeutics by 174.1% during the first quarter. AIGH Capital Management LLC now owns 1,015,541 shares of the company’s stock valued at $775,000 after acquiring an additional 645,000 shares in the last quarter. Institutional investors own 34.19% of the company’s stock.

About Aprea Therapeutics

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.